Press release
Bronchiectasis Pipeline Drugs Report 2025: Expert Insights on Upcoming Drugs, Clinical Development Stages, Competitive Landscape, and Future Opportunities in the Global Respiratory Diseases Market
Discover the latest drugs and treatment options in the Bronchiectasis Pipeline. Dive into DelveInsight's comprehensive report today! @ Bronchiectasis Pipeline Outlook [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from Bronchiectasis Pipeline Report
* On 18 September 2025, Boehringer Ingelheim announced a study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months.
* On 15 September 2025, Mannkind Corporation conducted a study (Part A) designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT). The primary objective of this study will be to compare the efficacy of Clofazimine Inhalation Suspension versus placebo as assessed by the co-primary endpoints, sputum culture conversion and change in Quality of Life-Bronchiectasis Respiratory Symptoms Score (QoL-B RSS).
* On 10 September 2025, Genentech Inc . organized a study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
* DelveInsight's Bronchiectasis Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Bronchiectasis treatment.
* The leading Bronchiectasis Companies such as AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A . and others.
* Promising Bronchiectasis Pipeline Therapies such as Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others.
Stay ahead with the most recent pipeline outlook for Bronchiectasis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Bronchiectasis Treatment Drugs [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Bronchiectasis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Bronchiectasis Pipeline Report also highlights the unmet needs with respect to the Bronchiectasis.
Bronchiectasis Overview
Bronchiectasis is an irreversible widening (dilation) of portions of the breathing tubes or airways (bronchi) resulting from damage to the airway wall. The most common cause is severe or repeated respiratory infections, often in people who have an underlying problem with their lungs or immune system.Most people develop a chronic cough, and some also cough up blood and have chest pain and recurrent episodes of pneumonia. Chest x-rays, computed tomography, and breathing tests are usually done to determine the extent and severity of the disorder.
Bronchiectasis Emerging Drugs Profile
* Benralizumab: AstraZeneca
Benralizumab is a monoclonal antibody used to treat eosinophilic asthma. Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. Currently, being evaluated in Phase III stage of clinical trial evaluation to treat Non-cystic Fibrosis Bronchiectasis.
* S1226: SolAeroMed
S1226 formulation consists of aerosolized carbon dioxide (CO2) and nebulized perflubron; which is delivered into the lung. The delivery of this formulation results in an immediate relaxant effect on the patient's constricted airways, supported by a lowering of surface tension in inflamed areas (resulting in enhanced bronchial dilation) and possible clearing of mucus plugs of blocked airways.The rescue treatment works on both physiological and biophysical principles offering a unique approach to relieving airway obstruction. CO2 is a potent, but short acting bronchial smooth muscle relaxant. Perflubron is a non-toxic (biocompatible) medical perfluorocarbon with mucolytic and surfactant properties that acts synergistically with CO2 to provide a much greater and more prolonged broncho-dilatory effect. The drug product is hypothesized to open constricted airways through at least three distinct mechanisms. Firstly, through the relaxant effect of CO2 (alone and dissolved into perflubron) on constricted airway smooth muscle; secondly, by lowering surface tension in the inflamed airways; and finally by possibly facilitating penetration and lubrication of mucus plugs, thus enhancing mucociliary clearance. Furthermore it works by an entirely different mechanism to the Ss-adrenergic agonists and thus complements, rather than replaces, existing treatments.
* Brensocatib: Insmed
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs.
Explore groundbreaking therapies and clinical trials in the Bronchiectasis Pipeline. Access DelveInsight's detailed report now! @ New Bronchiectasis Drugs [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Bronchiectasis Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Bronchiectasis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchiectasis Treatment.
* Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchiectasis market
Pulmonary Fibrosis Companies
AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A . and others.
Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Bronchiectasis Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
Unveil the future of Bronchiectasis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Bronchiectasis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Bronchiectasis Pipeline Report
* Coverage- Global
* Bronchiectasis Companies- AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A . and others.
* Bronchiectasis Pipeline Therapies- Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others.
* Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Bronchiectasis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Bronchiectasis Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Bronchiectasis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Bronchiectasis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Benralizumab: AstraZeneca
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* S1226: SolAeroMed
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CSL787: CSL Behring
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* AP-PA02: Armata Pharmaceuticals
* Drug profiles in the detailed report.....
* Inactive Products
* Bronchiectasis Key Companies
* Bronchiectasis Key Products
* Bronchiectasis- Unmet Needs
* Bronchiectasis- Market Drivers and Barriers
* Bronchiectasis- Future Perspectives and Conclusion
* Bronchiectasis Analyst Views
* Bronchiectasis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchiectasis-pipeline-drugs-report-2025-expert-insights-on-upcoming-drugs-clinical-development-stages-competitive-landscape-and-future-opportunities-in-the-global-respiratory-diseases-market]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bronchiectasis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchiectasis Pipeline Drugs Report 2025: Expert Insights on Upcoming Drugs, Clinical Development Stages, Competitive Landscape, and Future Opportunities in the Global Respiratory Diseases Market here
News-ID: 4192828 • Views: …
More Releases from ABNewswire
IBN Technologies Professional Bookkeeping Services Help E-Commerce Firms Save Ti …
IBN Technologies offers professional bookkeeping services for U.S. e-commerce businesses, helping online retailers track transactions, reconcile sales platforms, and manage tax compliance. Their services provide scalable solutions, timely reports, and actionable insights, enabling businesses to focus on growth while maintaining financial clarity and audit-readiness.
Miami, Florida - 22 Sep, 2025 - As e-commerce businesses in the U.S. expand digital storefronts, manage delivery logistics, and operate across multiple marketplaces, financial clarity has…
Eagle Vision Security: Leading the Way in Truck Yard Security Across Calgary
If you operate a truck yard in Calgary and are seeking a security partner who truly understands your industry, look no further than Eagle Vision Security. With our blend of advanced technology, experienced personnel, and a proactive security philosophy, we're not just protecting your property-we're protecting your business, reputation, and bottom line.
In Calgary's thriving transportation and logistics sector, truck yards are essential hubs where goods are stored, loaded, and dispatched.…
Pew Research Center Highlights: Study Smarter Insights Educators
Image: https://www.abnewswire.com/upload/2025/09/6b5a455611764535cd1618ed65d262d5.jpg
Can We Really Trust AI in Education?
Everyone who has ever used AI tools knows that they are not perfect yet and make mistakes. Even though they simplify many processes and save time, the threat of getting and spreading inaccurate information remains quite alarming, especially when talking about classrooms and universities worldwide. On the one hand, we can consider the positive AI impact on education and the way it helps…
Longevity World Cup Celebrates Athletes Who Can Reverse Aging
This competition is the perfect opportunity for biohackers to showcase their abilities to reverse aging
Image: https://www.abnewswire.com/upload/2025/09/524c90445305d892d671ac4c689ff079.jpg
BUDAPEST - September 22, 2025 - The Longevity World Cup [https://longevityworldcup.com/] invites longevity athletes to participate in a competition that rewards those who can reverse aging the most. By competing to optimize their biological clocks, these athletes have turned longevity into a measurable and dynamic competition. This kind of ethical experimentation brings humanity a step…
More Releases for Bronchiectasis
Bronchiectasis Market Insights and Future Outlook
Introduction
Bronchiectasis, a chronic respiratory condition characterized by abnormal widening of the bronchi, leads to persistent cough, recurrent infections, and progressive lung damage. Once considered rare, it is now increasingly diagnosed due to better imaging technologies and rising global awareness. The condition significantly impacts patient quality of life and requires lifelong management.
The Bronchiectasis Market is gaining traction as healthcare systems invest in respiratory disease management, pharmaceutical companies develop advanced inhaled antibiotics,…
Non-Cystic Fibrosis Bronchiectasis Market Thrives On Surging Respiratory Disease …
The Non-Cystic Fibrosis Bronchiectasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Non-Cystic Fibrosis Bronchiectasis Market?
The non-cystic fibrosis bronchiectasis market has grown strongly, from $3.5 billion in 2024 to $3.74 billion in 2025 at a CAGR of 6.9%.…
Key Influencer in the Non-Cystic Fibrosis Bronchiectasis Market 2025: Non-Cystic …
What industry-specific factors are fueling the growth of the non-cystic fibrosis bronchiectasis market?
The rising prevalence of respiratory diseases is expected to drive the non-cystic fibrosis bronchiectasis market. Respiratory diseases, influenced by environmental pollution and lifestyle factors, are increasing. Non-cystic fibrosis bronchiectasis, a condition affecting the lungs, requires specialized treatments and interventions. A report published by the UK's Office for Health Improvement and Disparities in June 2023 showed a rise in…
Transforming the Non-Cystic Fibrosis Bronchiectasis Market in 2025: Non-Cystic F …
What Is the Expected Size and Growth Rate of the Non-Cystic Fibrosis Bronchiectasis Market?
The market size of non-cystic fibrosis bronchiectasis has significantly expanded in the past few years. It is projected to prosper from $3.5 billion in 2024 to $3.74 billion in 2025, indicating a compound annual growth rate (CAGR) of 6.9%. The expansion in the previous interval is due to factors like increasing occurrence and prevalence, progressive advancements…
Bronchiectasis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Bronchiectasis Pipeline Insight 2024" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Bronchiectasis Research. Learn more about our innovative pipeline…
Bronchiectasis Global Market Research Report 2025
Bronchiectasis Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Access more details about this report at: https://www.research2reports.com/report-medical-devices/bronchiectasis-market/80987
The report firstly introduced the Bronchiectasis basics: definitions, classifications, applications and market overview; product…
